Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U4VT
|
|||
| Former ID |
DAP001265
|
|||
| Drug Name |
Trimethadione
|
|||
| Synonyms |
Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Epilepsy [ICD-11: 8A60-8A68] | Approved | [1], [2], [3] | |
| Pancreatic cancer [ICD-11: 2C10] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Anticonvulsants
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H9NO3
|
|||
| Canonical SMILES |
CC1(C(=O)N(C(=O)O1)C)C
|
|||
| InChI |
1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
|
|||
| InChIKey |
IRYJRGCIQBGHIV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 127-48-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
79578, 442280, 3140648, 4752043, 7847458, 8153431, 10321761, 10506232, 11112276, 11466543, 11467663, 11486126, 12075302, 14793827, 24899914, 29224614, 46504478, 47515477, 47589147, 47810920, 48334662, 48414586, 48416668, 49640650, 49698533, 49857709, 50100405, 50451607, 57322853, 57654646, 87688533, 92125435, 92307900, 92729771, 103193092, 103914246, 104309629, 117476493, 118232715, 121363106, 124801142, 124882159, 125563380, 126562866, 127307220, 127307221, 127307222, 127307223, 127307224, 127307225
|
|||
| ChEBI ID |
CHEBI:9727
|
|||
| ADReCS Drug ID | BADD_D02287 | |||
| SuperDrug ATC ID |
N03AC02
|
|||
| SuperDrug CAS ID |
cas=000127480
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Blocker | [4] |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | NCAM signaling for neurite out-growth | |||
| Nicotine Activity on Chromaffin Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 005856. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.